Epidermal Growth Factor Receptor (EGFR) (pTyr1173) antibody
Alternatives Western Blotting (WB), Immunohistochemistry (Formalin-fixed Sections) (IHC (f)), Immunoprecipitation (IP), ELISA
|2 references available|
|Quantity||0.1 mg (0.5 mg/ml)|
|Price||Product not available in this region.|
|Alternative name||EGF Receptor|
|Immunogen||Phosphorylated Human EGF Receptor Peptide|
|Cross-Reactivity||Mouse (Murine), Rat (Rattus), Dog (Canine)|
Epidermal Growth Factor (EGF) elicits a variety of cellular responses that are initiated by EGF Receptor (EGFR) binding and activation of intrinsic tyrosine kinase activity. EGFR, also known as ErbB1 or HER1, is a member of the ErbB class of receptor protein tyrosine kinases. It has an extracellular ligand-binding domain, a single transmembrane region, and a cytoplasmic region containing a protein tyrosine kinase domain and a c-terminal regulatory domain with many phosphorylation sites. Following ligand binding, EGFR forms homodimers and heterodimers with ErbB2. Specific C-terminal tyrosine residues are then autophosphorylated and, in turn, bind to adaptor proteins, kinases, or protein tyrosine phosphatases. Specifically, phosphorylated tyrosine 1173 (Y1173) interacts with Shc, SHP1, and PLCg, which mediate downstream signaling cascades and negative feedback regulation of EGFR activation. Inappropriate expression or mutations of EGFR and/or deregulation of its signaling pathways are associated with many types of cancer, making EGFR a promising target for cancer therapies.
The 9H2 monoclonal antibody recognizes the phosphorylated Y1173 in the regulatory domain of human EGFR.
1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
3. Please refer to us for technical protocols.
|Molecular Weight||175 kDa|
Related Products: ABIN967389
|Synonyms||ERBB, HER1, mENA, ERBB1, PIG61, Wa5, wa2, Erbb, Errp, wa-2, AI552599, 9030024J15Rik, ErbB-1, C-erb, D-EGFR, D-Egf, DEGFR, DER, DER flb, DER/EGFR, DER/faint little ball, DER/top, DER/torpedo, DmHD-33, EFG-R, EGF-R, EGFR, EK2-6, Egf, El, Elp, Elp-1, Elp-B1, Elp-B1RB1, HD-33, Torpedo/DER, Torpedo/Egfr, c-erbB, d-egf-r, dEGFR1, flb, l(2)05351, l(2)09261, l(2)57DEFa, l(2)57EFa, l(2)57Ea, pnt, top, top/DER, top/flb, DmelCG10079, CG10079, egfr, EGFR12, EGFR15, egfr1, Erbb2|
|Purification||Purified from tissue culture supernatant or ascites by affinity chromatography.|
|Buffer||Aqueous buffered solution.|
|Preservative||0.09% Sodium azide.|
|Storage||Store undiluted at 4°C.|
|Restrictions||For Research Use only|
Olayioye, Neve, Lane et al.: "The ErbB signaling network: receptor heterodimerization in development and cancer." in: The EMBO journal, Vol. 19, Issue 13, pp. 3159-67, 2000 (PubMed).
Mendelsohn, Baselga: "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 21, Issue 14, pp. 2787-99, 2003 (PubMed).